Montelukast Viatris

Montelukast, the active ingredient in Montelukast Viatris, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children as prescribed.

GNH USA supplies Montelukast Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways to manage several respiratory conditions.

Asthma: improves control and reduces frequency of bronchospasm in persistent asthma. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort in the stomach area. - Nausea: occasional feeling of queasiness. - Diarrhea: loose stools occurring intermittently. - Cough: transient irritation of the throat. - Sore throat: mild irritation of the pharynx.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Liver injury: signs of hepatitis such as jaundice or elevated enzymes. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.

Before prescribing Montelukast, consider the following precautions.

Pregnancy: safety not established; discuss risks with a healthcare provider. Breastfeeding: unknown excretion; weigh benefits against potential risks. Renal impairment: use with caution and monitor renal function. Hepatic impairment: dose adjustment may be needed; monitor liver enzymes. Concomitant phenobarbital or rifampin: may reduce drug effectiveness. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Montelukast can interact with other medicines; monitor the following.

Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: enzyme inducers that may lower montelukast plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure, requiring caution.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may raise montelukast levels. - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - Theophylline: combined use may affect bronchodilator response.